296 related articles for article (PubMed ID: 27664535)
1. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
[TBL] [Abstract][Full Text] [Related]
2. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
[TBL] [Abstract][Full Text] [Related]
4. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
[TBL] [Abstract][Full Text] [Related]
5. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.
Katzmann JA; Willrich MA; Kohlhagen MC; Kyle RA; Murray DL; Snyder MR; Rajkumar SV; Dispenzieri A
Clin Chem; 2015 Feb; 61(2):360-7. PubMed ID: 25451866
[TBL] [Abstract][Full Text] [Related]
6. A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients.
Chen S; Kiguchi T; Nagata Y; Tamai Y; Ikeda T; Kajiya R; Ono T; Sugiyama D; Nishikawa H; Akatsuka Y
Int J Hematol; 2021 Apr; 113(4):473-479. PubMed ID: 33507526
[TBL] [Abstract][Full Text] [Related]
7. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
[TBL] [Abstract][Full Text] [Related]
8. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.
Tang F; Malek E; Math S; Schmotzer CL; Beck RC
Am J Clin Pathol; 2018 Jul; 150(2):121-129. PubMed ID: 29901687
[TBL] [Abstract][Full Text] [Related]
9. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
10. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
11. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses.
Miyazaki K; Suzuki K
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):293-296. PubMed ID: 29472112
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
[TBL] [Abstract][Full Text] [Related]
13. Clearing drug interferences in myeloma treatment using mass spectrometry.
Kohlhagen MC; Mills JR; Willrich MAV; Dasari S; Dispenzieri A; Murray DL
Clin Biochem; 2021 Jun; 92():61-66. PubMed ID: 33691184
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.
Ludwig H; Milosavljevic D; Zojer N; Faint JM; Bradwell AR; Hübl W; Harding SJ
Leukemia; 2013 Jan; 27(1):213-9. PubMed ID: 22955329
[TBL] [Abstract][Full Text] [Related]
15. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
16. Correlations among different markers determined by immunochemical methods used for the diagnosis and monitoring of intact immunoglobulin multiple myeloma cases.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2012; 71(4):183-200. PubMed ID: 23755700
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
Sherbenou DW; Mark TM; Forsberg P
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
[TBL] [Abstract][Full Text] [Related]
18. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
Liang S; Feng W; Ma H; Zhang L; Jia C
Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
[TBL] [Abstract][Full Text] [Related]
19. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
[TBL] [Abstract][Full Text] [Related]
20. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.
Turner KA; Frinack JL; Ettore MW; Tate JR; Graziani MS; Jacobs JFM; Booth RA; McCudden CR; Keren DF; Delgado JC; Zemtsovskaja G; Fullinfaw RO; Caldini A; de Malmanche T; Katakouzinos K; Burke M; Palladini G; Altinier S; Zaninotto M; Righetti G; Melki MT; Bell S; Willrich MAV
Clin Chem Lab Med; 2020 Mar; 58(4):533-546. PubMed ID: 31940284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
